Top 10 Biotech Drugs Approved by the FDA

When you think about medical breakthroughs that have changed the course of treatment, biotech drugs sit at the top. These aren’t your standard pills. They’re engineered using living organisms, built through precision biology, and targeted at complex conditions like cancer, autoimmune disorders, and genetic diseases. In this article, you’ll get a practical breakdown of ten biotech drugs that have received FDA approval and made a major impact in the medical field. This isn’t just a list—it’s a clear look at how these drugs work, what they treat, and why they matter in your world as a healthcare professional, researcher, or biotech investor.

1. Humira (adalimumab)

You’ve likely heard of Humira—it’s been one of the top-selling biotech drugs globally for years. It’s a monoclonal antibody that blocks TNF-alpha, a protein involved in inflammation. This mechanism is what makes it effective in treating conditions like rheumatoid arthritis, Crohn’s disease, and ulcerative colitis.

If you work in rheumatology or gastroenterology, you already know how critical inflammation control is to patient outcomes. Humira was one of the first fully human monoclonal antibodies approved by the FDA, setting a high standard for biologics. Its success also paved the way for biosimilar competition, signaling a new era in biotech drug pricing and accessibility.

2. Keytruda (pembrolizumab)

Keytruda shifted how you approach cancer treatment. As a checkpoint inhibitor targeting PD-1, it boosts your immune system’s ability to recognize and destroy tumor cells. This is a game-changer for cancers like melanoma, non-small cell lung cancer, and head and neck squamous cell carcinoma.

One of the key benefits is its adaptability. You’ve probably seen it combined with chemotherapy or radiation for better outcomes. The FDA approved it through accelerated pathways due to its life-saving potential, and it’s one of the most widely studied immunotherapies in clinical trials today.

3. Enbrel (etanercept)

Enbrel is another TNF blocker that’s become a standard treatment for autoimmune diseases. Unlike Humira, it uses a fusion protein to intercept inflammatory signals before they reach cell receptors. You use it to manage rheumatoid arthritis, psoriasis, and ankylosing spondylitis.

What makes Enbrel stand out is its long-term safety record. It was among the earliest biotech drugs to demonstrate durable results in chronic conditions without the kinds of severe side effects seen with earlier immunosuppressants. If you deal with long-term care plans, Enbrel is likely in your toolkit.

4. Avastin (bevacizumab)

When you’re looking to starve tumors of their blood supply, Avastin is your go-to. This drug inhibits VEGF, a protein that encourages blood vessel formation in tumors. It’s FDA-approved for colorectal cancer, glioblastoma, and cervical cancer, among others.

Avastin is especially valuable because of its multi-tumor indication. It’s one of the few biologics that’s effective in solid tumors and has remained a staple in oncology despite newer drugs entering the market. You’ve probably seen it used in combination regimens where its anti-angiogenesis effect complements cytotoxic drugs.

5. Herceptin (trastuzumab)

If you’re treating HER2-positive breast cancer, Herceptin is essential. This monoclonal antibody binds to the HER2 receptor, slowing or stopping the growth of cancer cells. It’s also used in gastric cancers with the same HER2 overexpression.

Herceptin was one of the first targeted cancer therapies and remains a model for how precision medicine should work. You’ve likely followed its journey through clinical trials into everyday treatment, and seen how HER2 testing has become a routine part of cancer diagnostics because of it.

6. Eylea (aflibercept)

Eylea brings biotech into the world of ophthalmology. It’s a VEGF inhibitor, like Avastin, but used to treat age-related macular degeneration (AMD), diabetic retinopathy, and retinal vein occlusion. You administer it via intravitreal injection to prevent vision loss in these progressive diseases.

The reason Eylea stands out is its extended duration of action. You can reduce injection frequency compared to older therapies, which improves adherence. If you’re an ophthalmologist, you’ve probably seen how it helps maintain independence and quality of life for your aging patients.

7. Opdivo (nivolumab)

Opdivo is another checkpoint inhibitor that’s reshaped how you manage cancer. Like Keytruda, it blocks PD-1 and helps your immune system fight cancer cells. It’s FDA-approved for melanoma, renal cell carcinoma, and Hodgkin lymphoma, among others.

What’s unique about Opdivo is its strong performance in combination therapy. You’ll often see it used with Yervoy (ipilimumab) for enhanced immune activation. Its versatility across multiple tumor types makes it one of the cornerstones of modern immuno-oncology.

8. Soliris (eculizumab)

Soliris treats ultra-rare diseases, which gives you a different view into biotech’s role in niche medicine. It inhibits complement protein C5, a key player in immune-mediated destruction of red blood cells. You prescribe it for conditions like paroxysmal nocturnal hemoglobinuria (PNH) and atypical hemolytic uremic syndrome (aHUS).

Soliris is notable for its price and the precision of its indications. You’re not using it as a first-line treatment—its administration is tightly controlled and based on genetic or diagnostic confirmation. It shows how biotech innovation can serve small populations with high unmet needs.

9. Dupixent (dupilumab)

Dupixent is an interleukin inhibitor that targets IL-4 and IL-13 signaling. It’s approved for moderate-to-severe atopic dermatitis, asthma, and chronic rhinosinusitis with nasal polyps. If you’re a dermatologist or allergist, this drug likely changed your practice.

What makes Dupixent valuable is its steroid-sparing effect. You can manage chronic inflammation without relying heavily on corticosteroids, reducing long-term side effects. It’s especially effective in patients with multiple allergic comorbidities, showing how biotech can connect dots across specialties.

10. Spinraza (nusinersen)

Spinraza gave children with spinal muscular atrophy (SMA) a lifeline. It’s an antisense oligonucleotide that modifies RNA splicing to increase production of the SMN protein, which is critical for motor neuron survival. It was the first FDA-approved treatment for SMA.

As a neurologist or pediatrician, you’ve likely witnessed the dramatic improvement Spinraza brings—especially in infants. It’s administered intrathecally, which presents logistical challenges, but its effect on survival and motor function is unmatched in SMA treatment to date.

What are the top biotech drugs approved by the FDA?

• Humira (arthritis)
• Keytruda (cancer)
• Enbrel (autoimmune diseases)
• Avastin (solid tumors)
• Herceptin (HER2+ cancers)
• Eylea (AMD)
• Opdivo (PD-1 blocker)
• Soliris (rare diseases)
• Dupixent (eczema/asthma)
• Spinraza (SMA)

In Conclusion

Biotech drugs have moved far beyond niche treatments—they now define standards of care across multiple specialties. If you’re involved in drug development, clinical research, or frontline treatment, these FDA-approved therapies give you tools that are deeply targeted and biologically intelligent. As research continues to push boundaries, you’ll find that biotech doesn’t just supplement traditional medicine—it’s shaping the future of how you treat, prevent, and even cure.

For expert insights on FDA-approved biotech breakthroughs transforming cancer care, rare disease treatment, and autoimmune therapy, follow me on Golden.